FindTrial
Sign In

Safety and Efficacy of Upadacitinib in the Treatment of Patients with Moderate-to-Severe Inflammatory Bowel Disease: A Single-Center, Retrospective, Real-World Study

Safety and Efficacy of Upadacitinib in the Treatment of Patients with Moderate-to-Severe Inflammatory Bowel Disease: A Single-Center, Retrospective, Real-World Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500113659
Enrollment
Unknown
Registered
2025-12-01
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Disease

Interventions

Observation group of upatinib for moderate to severe inflammatory bowel disease:None

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Meet the Chinese Guidelines for the Diagnosis and Treatment of Crohn’s Disease (Guangzhou, 2023) and the Chinese Guidelines for the Diagnosis and Treatment of Ulcerative Colitis (Xi’an, 2023), and be diagnosed with moderate-to-severe inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC). (2) Patients with moderate-to-severe IBD: CD patients with a Best CDAI score > 220 or UC patients with a modified Mayo score > 5. (3) Patients who received upadacitinib (UPA) treatment and followed up regularly.

Exclusion criteria

Exclusion criteria: Patients whose follow-up duration was less than 4 weeks from the start of upadacitinib (UPA) treatment, regardless of whether they continued taking UPA or not.

Design outcomes

Primary

MeasureTime frame
Clinical remission rate;—

Secondary

MeasureTime frame
Endoscopic remission rate;Adverse reaction;—

Countries

China

Contacts

Public ContactLing Liu

West China Hospital, Sichuan University

lingzipurple@163.com+86 189 8060 6772

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026